SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

SYN-007

TOVX·Theriva Biologics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Not estimable; the asset is now owned by Biossil Labs, which has not announced clinical timelines
Why 2/10
SYN-007 was sold by Theriva to Biossil Labs on October 30, 2026, a completed transaction. There is no upcoming binary catalyst for this drug at Theriva; the asset is no longer in its pipeline. ImpactScore is low because the drug is preclinical, already divested, and represents no further binary risk or opportunity for TOVX stock.
Actionable Insight NEUTRAL

SYN-007 is no longer part of Theriva Biologics. The sale to Biossil Labs closed October 30, 2026. Investors should watch Theriva's Q3 2026 earnings on November 10 for cash runway details and updates on VCN-01, the company's sole remaining pipeline asset. Any future SYN-007 value to Theriva depends entirely on Biossil's ability to advance the program, over which Theriva has no control.

Price Chart

Loading chart...

Executive Summary

SYN-007 is a preclinical delayed-release oral formulation of the beta-lactamase enzyme ribaxamase, designed to protect the gut microbiome from damage during oral antibiotic therapy. Theriva Biologics (TOVX) sold SYN-007, along with the rest of its antibiotic-degrading enzyme portfolio, to OpenAI-backed Biossil Labs on October 30, 2026 for $350K upfront plus up to $91M in contingent milestones and royalties. Theriva no longer controls or develops SYN-007; the company is now focused solely on its VCN-01 oncolytic adenovirus platform for cancer. For a TOVX investor, SYN-007 is a historical asset with no upcoming catalysts tied to the company.

How It Works

SYN-007 is an oral enzyme (beta-lactamase) that breaks down certain antibiotics in the gut. It is designed to be taken together with oral antibiotics like amoxicillin to protect the natural gut bacteria from being wiped out, while not interfering with the antibiotic's absorption into the bloodstream. It is a reformulated, delayed-release version of an earlier drug called SYN-004 (ribaxamase).

Trial Status

SYN-007 never entered human clinical trials. Preclinical proof-of-concept was demonstrated in dogs, where SYN-007 co-administered with oral amoxicillin/clavulanate protected the gut microbiome without affecting systemic antibiotic absorption. The parent compound SYN-004 (ribaxamase) had reached Phase 2b for preventing C. difficile infection with IV antibiotics. SYN-007 was designed as a follow-on reformulation for use with oral antibiotics.

The Two-Sided Case

▲ Bull Case2
Theriva eliminated burn on a preclinical asset it had already deprioritized, receiving $350K upfront and retaining upside via up to $91M in milestones and low single-digit royalties on any future sales.
SYN-007 addresses a large addressable market: oral amoxicillin/clavulanate accounted for over 70 million U.S. prescriptions per year, and protecting the gut microbiome during antibiotic treatment is a validated medical need.
▼ Bear Case4
SYN-007 never advanced beyond preclinical (dog) studies and had no confirmed path to human trials, making the milestone/royalty upside highly speculative.
Theriva received only $350K upfront against a ~$9M market cap (net ~$210K after paying PREV ABR LLC) and must share 33-50% of future proceeds with PREV, capped at $13M, substantially diluting any potential upside.
Theriva now has zero control over SYN-007's development, which depends entirely on Biossil Labs' execution and funding priorities.
Theriva's focus shifts entirely to VCN-01, an early-stage oncolytic adenovirus pipeline that carries its own substantial development and financing risk.

Upcoming Catalysts

  • None for Theriva: SYN-007 was sold to Biossil Labs on October 30, 2026, removing it from Theriva's pipeline. Future development decisions rest with Biossil (an OpenAI-backed startup).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Theriva Biologics, Inc. 8-K TOVX ·Originating report

Sources · 7

Hover a chip for the title
1 therivabio.com2 fiercebiotech.com3 sec.gov4 biospace.com5 pmc.ncbi.nlm.nih.gov6 stocktitan.net7 tipranks.com